Related Experiment Video
Updated: May 15, 2026

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Neonatal screening for congenital adrenal hyperplasia in Japan
Toshihiro Tajima1, Kaori Fujikura, Masaru Fukushi
1Department of Pediatrics, Hokkaido University School of Medicine, N15, W7, Kita-Ku, Sapporo 060-8638, Japan. tajeari@med.hokudai.ac.jp
Insights
Congenital adrenal hyperplasia (CAH) screening in Japan uses advanced methods like LC-MS/MS to improve accuracy. This technology enhances early detection and treatment effectiveness for newborns, particularly preterm infants.
Area of Science:
- Endocrinology
- Genetics
- Neonatal screening
Background:
- Congenital adrenal hyperplasia (CAH) screening has been conducted nationwide in Japan since 1989.
- The incidence of 21-hydroxylase deficiency in Japan is approximately 1/18,000, comparable to global rates.
- Cost-benefit analyses confirm the effectiveness of early CAH detection and treatment in Japan.
Purpose of the Study:
- To address the high false-positive rates in CAH screening for preterm infants.
- To enhance the positive predictive value of newborn screening for CAH.
- To evaluate and suggest improved screening methodologies for CAH in Japan.
Main Methods:
- Utilized 21-hydroxylase gene (CYP21A2) analysis on dried blood spots.
- Employed high-performance liquid chromatography (HPLC) for 17-hydroxyprogesterone measurement.
- Implemented tandem mass spectrometry (LC-MS/MS) as a current screening technique.
Main Results:
- The study highlights the ongoing efforts to refine CAH screening protocols.
- LC-MS/MS has been adopted to improve the accuracy of screening.
- The incidence of CAH in Japan is consistent with international data.
Conclusions:
- Tandem mass spectrometry (LC-MS/MS) is recommended for future CAH screening in Japan.
- Improving screening accuracy is crucial for effective early detection and management of CAH.
- Continued advancements in screening technology are vital for neonatal health outcomes.
Abstract:
A nationwide screening test for congenital adrenal hyperplasia (CAH) was first initiated in Japan in 1989, over 20 years ago, and it is now 30 years since a pilot study was initiated in Sapporo in 1982. The incidence of 21-hydroxylase deficiency in Japan is about 1/18,000 persons, which is similar to that in other countries. The effectiveness of early detection and treatment of CAH in Japan has been demonstrated by cost-benefit analyses. However, the false-positive rate of CAH screening in preterm infants remains high compared to screening tests for term infants. To improve the positive predictive value, we have employed 21-hydroxylase gene (CYP21A2) analysis on dried blood spots and high performance liquid chromatography (HPLC) to measure 17-hydroxyprogesterone, and currently use tandem mass spectrometry (LC-MS/MS) as a screening technique. We suggest that LC-MS/MS should be used in the future to improve the accuracy of CAH screening in Japan.
Related Concept Videos
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Teratogenicity
Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
